tradingkey.logo
tradingkey.logo
Search

Sol Gel Technologies Ltd

SLGL
Add to Watchlist
74.010USD
+2.020+2.81%
Close 07/02, 13:00ETQuotes delayed by 15 min
241.94MMarket Cap
LossP/E TTM

More Details of Sol Gel Technologies Ltd Company

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sol Gel Technologies Ltd Info

Ticker SymbolSLGL
Company nameSol Gel Technologies Ltd
IPO dateFeb 01, 2018
CEO- -
Number of employees34
Security typeOrdinary Share
Fiscal year-endFeb 01
AddressGolda Meir 7
CityNESS-ZIONA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code- -
Phone97289313433
Websitehttp://www.sol-gel.com
Ticker SymbolSLGL
IPO dateFeb 01, 2018
CEO- -

Company Executives of Sol Gel Technologies Ltd

Name
Name/Position
Position
Shareholding
Change
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--
Mr. Itai Arkin
Mr. Itai Arkin
Director
Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--

FAQs

Who are the top five shareholders of Sol Gel Technologies Ltd?

The top five shareholders of Sol Gel Technologies Ltd are: Mr. Moshe (Mori) Arkin

How many institutions hold shares of Sol Gel Technologies Ltd (SLGL)?

As of 2026Q1, 39 institutions hold shares of Sol Gel Technologies Ltd, with a combined market value of approximately 1.00M, accounting for 30.93% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -175336.00.